OBJECTIVE: @entity463 with @entity9275 dehydrogenase 1/2 mutations comprise a biologically distinct subgroup of @entity463 . We studied @entity9275 dehydrogenase 1/2 mutant @entity463 at the clinical, molecular and radiological levels to define their clinical features, including the prognostic value of @entity9275 dehydrogenase 1/2 mutations compared with @entity9275 dehydrogenase 1/2 wild-type @entity463 . METHODS: We investigated 128 newly diagnosed @entity463 @entity1 who were treated at our institute between January 2005 and May 2013. @entity9275 dehydrogenase 1/2 mutation status was determined using pyrosequencing. @entity8634 deoxyribonucleic acid methyltransferase promoter methylation and 1p/19q co-deletions were also analyzed using pyrosequencing and multiplex ligation-dependent probe amplification, respectively. RESULTS: @entity9275 dehydrogenase 1/2 mutations were detected in 10 of 128 @entity1 (7.8%). @entity9275 dehydrogenase 1/2 mutations were correlated with a younger age, the presence of an oligodendroglial component and 1p/19q co-deletions and a longer survival time. The interval from initial symptom to initial operation did not differ according to @entity9275 dehydrogenase 1/2 mutation status (median interval: 2.3 versus 1.2 months; P = 0.13). Two of three @entity9275 dehydrogenase 1/2 mutant @entity463 harboring 1p/19q co-deletions had an oligodendroglial component and were associated with a prolonged survival time. Multivariate analysis of 90 @entity1 treated with @entity2903 -based chemoradiotherapy indicated that age, extent of resection, postoperative Karnofsky performance score and @entity8634 deoxyribonucleic acid methyltransferase promoter methylation were correlated with better survival. @entity9275 dehydrogenase 1/2 mutations showed a trend for improved survival (P = 0.068). CONCLUSIONS: Most @entity9275 dehydrogenase 1/2 mutant @entity463 have a short clinical history, and some @entity9275 dehydrogenase 1/2 mutant @entity463 harboring 1p/19q co-deletions behave like @entity5 . @entity9275 dehydrogenase 1/2 mutations may have a positive prognostic impact on the Japanese population.

XXXX with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8634 :: ('MESH:C008449', 'Chemical') :: ['O-6-methylguanine'] @entity5 :: ('MESH:D009369', 'Disease') :: ['oligodendroglial tumors'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide'] @entity463 :: ('MESH:D005909', 'Disease') :: ['Glioblastomas', 'glioblastomas', 'glioblastoma'] @entity9275 :: ('MESH:C034219', 'Chemical') :: ['Isocitrate', 'isocitrate']
@entity463 :: (MESH:D005909,Disease) :: ['Glioblastomas']
